<DOC>
	<DOCNO>NCT01295320</DOCNO>
	<brief_summary>The subject include study subject participate study NCT00434577 . These subject vaccinate candidate Herpes Zoster ( HZ ) vaccine Month 0 Month 2 follow Month 12 , Month 24 Month 36 ( study NCT00434577 ) safety immunogenicity . This long term follow study ( ZOSTER-024 [ 114825 ] ) evaluate immune response safety previously administer candidate HZ vaccine Months 48 , 60 72 . The study visit schedule approximately one year interval first visit ZOSTER-024 . Blood sample evaluation cellular humoral immunity take subject visit . Information safety occurrence HZ also collect visit .</brief_summary>
	<brief_title>Study Long Term Immune Responses Safety GSK Herpes Zoster Vaccine Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol Previous participation study NCT00434577 member intermediate dose active vaccine group Written inform consent obtain subject Having participate another study time NCT00434577 study end subject expose investigational noninvestigational product ; concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product Administration immunoglobulins and/or blood product within 3 month precede first blood draw Having receive vaccine contain vaccine component , time study end study NCT00434577 Having receive vaccine HZ time study end study NCT00434577 Subject receive complete vaccination course 2 dos intermediate dose active vaccine study NCT00434577</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Herpes Zoster</keyword>
	<keyword>vaccine</keyword>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
</DOC>